A Phase I/II, Open Label, Proof of Concept Study to investigate Tolerability and Safety of Treatment with Recombinant Human C1 Inhibitor in Patients with Preeclampsia.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Oct 2022 According to the EudraCT record the study has been Prematurely Ended in Netherlands
04 Mar 2020 According to a Pharming Group NV media release, a small safety study expected to read out headline data in 2020 and a larger Phase II proof of concept study which will follow on from a successful outcome of the first part.
11 Jun 2019 According to a Pharming Group NV media release, The second (open label, proof of concept) part of the study (following approval by the ethics committees) is planned to include 30 patients in total recruited between two centres, of which one is in the Netherlands and one in Australia. The entire study is expected to last approximately one year, depending on the rate of recruitment and the early stage safety performance.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com